3 Glu 129 (G129E) (14) ], which has lost its lipid phosphatase activity but not its protein phosphatase activity, inhibits the migration of some tumor cells, suggesting that other mechanisms may be involved (13, 15) .
To examine how PTEN regulates motility, we used an in vitro wound-healing assay (16) and three human glioma cell lines-U373, U138, and U87-that lack detectable PTEN protein as a result of genetic lesions (1) . Cells were plated on coverslips and allowed to grow to confluency, and the monolayer was scratched with a glass microneedle to initiate cell migration. One hour later, cells at the leading edge of either side of the wound were microinjected with a control expression vector encoding green fluorescent protein (GFP) or with an expression vector encoding hemagglutinin (HA) epitope-tagged wild-type PTEN. U373 cells injected with control plasmid remained at the front of the migrating edge even after 16 hours, whereas cells expressing wild-type PTEN did not migrate and were overtaken by noninjected cells (Fig.   1 ). Wild-type PTEN also inhibited cell migration in U138 and U87 cells (17) . To examine the requirement for PTEN's catalytic activity, cells were injected with expression vectors encoding either the PTEN(G129E) mutant that lacks lipid phosphatase activity but retains protein phosphatase activity (Fig. 1, C and G) , or the PTEN(C124S) mutant that lacks both lipid and protein phosphatase activity (Fig. 1, D and H) (18) . As reported, the lipid phosphatase activity of PTEN was not required for inhibition of migration, but the protein phosphatase activity of PTEN was required (15) .
To investigate whether other regions of PTEN are required for inhibition of cell migration, several deletion mutants were tested in the same assay ( Fig. 2A) . A mutant in which the catalytic phosphatase domain was completely deleted (PTEN⌬N) was as efficient as wild-type PTEN in inhibiting the migration of U373 (Fig. 2) , U138, and U87 (17) . This result was confirmed by microinjecting U373 cells with recombinant PTEN⌬N protein made in Escherichia coli (17, 19) . Two additional deletions of the PTEN⌬N construct, one to remove the PDZ binding motif at the extreme C terminus [PTEN⌬N(⌬PDZBD)] and another to remove all sequences C terminal to the C2 domain (PTEN-C2), were also as efficient as wild-type PTEN in inhibiting the motility of U373 cells (Fig. 2, A and B) . To check that not all C2 domains inhibit the migration of these cells, constructs expressing either the Ca 2ϩ -dependent C2A domain or the Ca 2ϩ -independent C2B domain of synaptotagmin were injected (20) , and these had no inhibi- tory effect on migration (Fig. 2, A and B) . Thus, PTEN inhibited the migration of glioma cells specifically through its C2 domain.
Although the isolated C2 domain inhibited migration, catalytically inactive PTEN did not, suggesting that in the full-length protein, C2 domain activity is attenuated. PTEN contains five major phosphorylation sites and these are all located in the Cterminal 50 -amino acid tail region (Ser 370 , Ser 380 , Thr 382 , Thr 383 , and Ser 385 ) and have been implicated in controlling PTEN activity (21) (22) (23) (24) . To examine whether phosphorylation at these sites affects the activity of the C2 domain, we first introduced four alanine substitutions at Ser 380 , Thr 382 , Thr 383 , and Ser 385 into full-length but catalytically inactive PTEN (Fig. 3A,   PTEN(C124S)-A4) . Removal of these four phosphorylation sites completely rescued the ability of catalytically inactive PTEN to inhibit migration of U373 cells (Fig. 3A) . To identify which of the four sites is critical, individual residues were mutated to alanine (Fig. 3A) . Mutation of the single residue Thr 383 completely rescued inhibition of migration by PTEN(C124S), whereas mutation of any of the other three phosphorylation sites did not (Fig. 3, A and B) . Thus, in the full-length protein, dephosphorylation of Thr 383 is required to allow the C2 domain to inhibit migration, and this depends on the protein but not lipid phosphatase activity of PTEN. To confirm that dephosphorylation of Thr 383 is critical for inhibition of glioma cell migration by PTEN, a phosphorylated Thr 383 mimetic construct was generated (PTEN-T383D) by introducing an aspartic acid residue at this site in either a wild-type or a G129E mutant PTEN molecule [ Fig. 3A (17) ]. This substitution completely abrogated the ability of these two proteins to inhibit migration (Fig.  3A) . It did not, however, affect the lipid phosphatase activity of wild-type PTEN, because PTEN-T383D was as efficient as wild-type PTEN in reducing PIP 3 -mediated activation of the serine/threonine kinase AKT when transfected into HeLa cells (17) .
The crystal structure of PTEN (lacking the C-terminal tail) reveals extensive intramolecular interactions between independently folding phosphatase and C2 domains (25) . To examine whether phosphorylation at Thr 383 might affect this interaction, we first examined whether the N terminus of PTEN can be immunoprecipitated with the . The 9E10 antibody to Myc was used to immunoprecipitate the PTEN constructs. Phosphorylation of the constructs was detected and quantitated by autoradiography using a phosphorimager. The 9E10 antibody to Myc was also used to control for the expression levels of the constructs immunoprecipitated. The circled P represents phosphorylated PTEN; WB, Western blot.
C terminus after expressing individual fragments in transfected COS-7 cells. Immunoprecipitation of the N terminus [residues 1 to 175; PTEN(C124S)⌬C] efficiently precipitated the C terminus [residues 175 to 403; PTEN⌬N] and vice versa (Fig. 4A) . However, a C-terminal fragment lacking the 50 -amino acid tail (residues 175 to 353; PTEN-C2) could not be immunoprecipitated with the N terminus (Fig. 4A) , indicating that the C-terminal tail is essential for stable interaction. To determine whether phosphorylation of the tail affects this interaction, the N-terminal domain from a catalytically inactive version of PTEN [PTEN(C124S)⌬C] was coexpressed with a C-terminal domain containing either the four phosphorylation-site substitutions (PTEN⌬N-A4) (Fig. 3C, lanes 1  and 2) . Furthermore, phosphate incorporation into the catalytically active PTEN-D4 mutant was the same as that incorporated into catalytically active PTEN in which all five major phosphorylation sites (i.e., including Thr 383 ) had been mutated (Fig. 3C,  lanes 2 and 3) . The catalytically inactive PTEN is, therefore, phosphorylated at Thr 383 , whereas wild-type PTEN is not phosphorylated at this site.
We conclude that PTEN can inhibit the migration of human glioma cells through its C2 domain, independent of its effects on the PI 3 kinase pathway. The migration of U373 cells is unaffected by wortmannin (100 nM), whereas U87 migration is blocked by this inhibitor (17) . It appears, therefore, that wild-type PTEN inhibits the migration of U373 cells solely through the activity of its C2 domain, whereas the inhibition of U87 migration occurs through both the C2 and the lipid phosphatase domains. The activity of the C2 domain is controlled by the phosphorylation state of Thr 383 . When phosphorylated by an unknown kinase, the C2 domain is inactive, and when dephosphorylated the C2 domain is active and able to interfere with migration. Furthermore, the protein phosphatase activity of PTEN is required for dephosphorylation of Thr 383 . Because the 12-residue peptide sequence surrounding Thr 383 (YSDTTDSDPENE) is extremely acidic (five Asp or Glu and four phosphorylated Ser or Thr residues) and matches the optimal peptide substrates reported for PTEN, it is possible that dephosphorylation of Thr 383 is mediated by an intramolecular autocatalytic activity (18) . Alternatively, the protein phosphatase activity of PTEN could activate another protein phosphatase or inactivate a kinase, which would then lead to dephosphorylation of Thr 383 . In tumors containing catalytically inactive PTEN, the antimigratory activity of the C2 domain may be lost along with the lipid phosphatase activity, and this could have important implications for tumor progression.
